The partnership enhances Emcure’s existing diabetes portfolio and reinforces its efforts to expand access to affordable, high ...

Emcure Pharmaceuticals partners with Sanofi India to distribute and promote oral anti-diabetic products in India.

KPRDO acknowledges Emcure’s positive response on exclusive stockist appointment for special category sales: Nandita ...

Emcure Pharmaceuticals Ltd. and Sanofi India Limited today entered into an exclusive distribution and promotion agreement for ...

Emcure Pharmaceuticals and Sanofi India have entered in a partnership to distribute and promote Sanofi’s oral anti-diabetic ...

Emcure Pharmaceuticals and Sanofi India have partnered in an exclusive distribution and promotion agreement for Sanofi's oral ...

Over 100 million Indians are living with type 2 diabetes and its complexities in India,' said Eric Mansion from Sanofi.

Emcure Pharmaceuticals and Sanofi India announce exclusive distribution agreement for Sanofi's oral anti-diabetic products in ...

Emcure Pharmaceuticals and Sanofi India have announced a distribution agreement. Emcure will promote Sanofi India's oral anti ...

Q2 2025 saw deal value drop 62% as large-ticket M&A dried up; investors pivot to focused platforms in pharma, hospitals, ...

Emcure Pharma and Sanofi India announced that they entered into an exclusive distribution and promotion agreement for the latter's oral anti-diabetic products in India, effective immediately. Emcure ...

The NSE Nifty 50 ended 16.25 points or 0.06% higher at 25,212.05, while the BSE Sensex closed 63.57 points or 0.08% up at 82,634.48.